EMCDDA logo Annual report on the state of the drugs problem in the European Union 2001

Home of the Annual Report
Introduction to the annual report
Chapter 1: Drug demand and drug supply
Chapter 2: Responses to drug use
Chapter 3: Selected issues
Chapter 4: The drugs problem in central and eastern European countries
Figures and tables
 
Download complete report in 12 languages  in Adobe PDF  format
News Releases and press information
 
 

Search Site Map Contact

2001 Annual Report data library

This data library has been put together to facilitate your consultation of the data, figures and sources that have been used in the compilation of the 2001 Annual report.
 

This data library provides you with direct access to:

  • all the figures and tables contained within the report

  • a set of complementary statistical tables which form the basis of the figures created

  • details on the sources of the information used in the report.

Each year the Reitox national focal points provide to the EMCDDA a report on the national drug situation in their respective countries. The national drug situation reports presented to the EMCDDA in 2000 are available online.

Drug use

Drug use in the general population

Figures
Recent use (last-12-months prevalence) of cannabis, amphetamines and cocaine among young adults in some EU countries measured by national population surveys (Figure 1, bar chart)

Evolution of lifetime experience and recent use (last-12-months prevalence) of cannabis among adults in some EU countries during the 1990s, measured by population surveys (Figure 2, bar chart)

Lifetime experience of cannabis, amphetamines and cocaine among adults in some EU countries, measured by national population surveys (Figure 1 OL, bar chart)

Last-12-months prevalence of ecstasy and cocaine by age group in England and Wales, 1998 (Figure 2 OL, bar chart)

Lifetime experience of cannabis among all adults and among young adults in some EU countries, measured by national population surveys (Figure 3 OL, bar chart)

Lifetime experience of cannabis among adults (males and females) in some EU countries, measured by national population surveys (Figure 4 OL, bar chart)

Lifetime experience of cannabis among adults in Finland by level of urbanisation, 1998 (Figure 5 OL, bar chart)

Lifetime experience and last-12-months prevalence of cannabis among adults in some EU countries, measured by national population surveys (Figure 6 OL, bar chart)

Statistical tables
Lifetime prevalence of drug use in recent nation-wide surveys among the general population in some EU countries

Last-12-months prevalence of drug use in recent nation-wide surveys among the general population in some EU countries

 

Drug use in the school population

Statistical table
Lifetime prevalence of use of different illegal drugs among 15- to 16- year-old students in recent nation-wide school surveys in some EU countries

 

Problem drug use

Figures
National prevalence estimates of problem drug use in the EU and Norway, 1996-98 (Figure 3, map)

Relative incidence (number of new cases per year) of problem opiate users who eventually went for treatment or to social services, for Belgium, Lisbon and Budapest - estimated by the Brookmeyer and Liao method (Figure 4, line chart)

Relative incidence (number of new users per year) of problem opiate users who eventually went for treatment, for the three biggest Italian southern regions - estimated through back-calculation (Figure 5, line chart)

Statistical tables
National prevalence estimates of problem drug use in the EU and Norway (absolute numbers of problem drug users), 1996-98 (Table 1 OL)

National prevalence estimates of problem drug use in the EU and Norway (prevalence rates of problem drug use per 1000 inhabitants aged 15-64), 1996-98 (Table 2 OL)


Health consequences of drug use

Demand for treatment

Figures
All clients admitted for treatment for heroin, cannabis, amphetamines, cocaine and other substances in some member states (Figure 6, bar chart)

Evolution of new clients admitted to treatment for heroin and cannabis in some Member States (Figure 7, line chart)

Trends for all clients admitted to treatment for heroin, cannabis and cocaine (Figure 7 OL, line chart)

All and new clients admitted to treatment for cannabis and cocaine use in some Member States, 1999 data (Figure 8 OL, bar chart)

Proportion of injectors among all and new clients admitted to treatment for heroin use in some Member States, 1999 data (Figure 9 OL, bar chart)

Statistical tables

Some characteristics of persons treated for drug problems in the EU

Some characteristics of persons in the EU treated for drug problems for the first time

Some characteristics of women treated for drug problems in the EU

Some characteristics of men treated for drug problems in the EU

Sources for tables on characteristics


Drug-related infectious diseases


Figures

Prevalence of HIV infection among injecting drug users in EU Member States, 1996-2000 (Figure 8, map)

Prevalence of antibodies to hepatitis C infection among injecting drug users in EU Member States, 1996-2000 (Figure 9, map)

AIDS cases diagnosed in 1999 in injecting drug users per million population (Figure 16 OL, map)

Prevalence of antibodies against hepatitis B virus among injecting drug users in EU Member States, 1996-2000 (Figure 17 OL, map)

Prevalence of current HBV infection (HbsAg) in IDUs from different sources (Figure 28, line chart)

Trends in HIV prevalence in IDUs from different sources, all ages and age under 25 (Figure 24)

Notified cases of HIV related to IDU (Figure 25, line chart)

Incidence of AIDS related to IDU in EU Member States (Figure 26, line chart)

Needle sharing among injecting drug users in some EU Member States (Table 6 OL)

Provision of syringe exchange programmes in some EU countries (Figure 30, bar chart)

Syringes distributed or exchanged through syringe exchange programmes per estimated IDU per year (Figure 18 OL, bar chart)

Provision, utilisation and coverage of syringe exchange programmes (SEPs) for injecting drug users (IDUs) and coverage of pharmacies in some European countries, as reported by national focal points, 2000 (Table 7 OL)

Provision of HIV counselling and testing, HIV treatment and HBV vaccination for injecting drug users (IDUs) in some European countries, as reported by national focal points, 2000 (Table 8 OL)

Trends in HCV prevalence in IDUs from different sources, all ages and age under 25 (Figure 27, line chart)

Estimated future healthcare costs of one year of drug-related infections for HCV, HBV and HIV, in millions of euro for 10 Eu countries (total for EU as a whole EUR 1.89 billion - 1995 price level) (Figure 29, bar chart)


Statistical tables
Prevalence of HIV infection among injecting drug users in EU Member States, 1996-2000 (table for Figure 8)

Prevalence of HIV infection among injecting drug users in EU Member States, 1996-2000 (references for Figure 8)

Prevalence of antibodies against hepatitis C among injecting drug users in EU countries (table for Figure 9)

Prevalence of antibodies against hepatitis C among injecting drug users in EU countries (references for Figure 9)

Prevalence and trends in HBV current infection (% with HbsAg) among injecting drug users in EU Member States, all ages, 1996-2000) (Figure 28)

Trends in HCV antibody prevalence (%) among injecting drug users in EU Member States, all ages, 1996-2000 (Figure 27)

Incidence of AIDS cases related to injecting drug use in the EU (by 31 December 2000), 1985-2000 (Figure 26)

Trends in HIV infection (%) among injecting drug users in EU Member States, all ages and age under 25, 1996-2000 (Figure 24)

Trends in notified HIV cases or positive HIV tests among injecting drug users in EU Member States, 1991-199 (Figure 25)

Drug-related deaths


Figures
Trends in acute drug-related deaths in some EU countries, 1995-99 (Figure 10, line chart)

Mortality from all causes in cohorts of opiate users recruited in treatment centres in several EU countries or cities. Standardised mortality rates (males and females) (Figure 11, line chart)

Proportion of abuse of opiate and non-opiate drugs among the cases of drug-related deaths, valid percentages based on cases with known toxicology (Figure 10 OL, bar chart)

Proportion of people over 30 among drug-related deaths in some EU countries, 1986 and 1999 (Figure 11 OL, bar chart)

Definitions of 'acute drug-related death' in EU Member States, as used in the EMCDDA annual report, and reported in national reports (Box 1 OL)Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland and Italy, Luxembourg, the Netherlands, Portugal, Sweden, Spain, United Kingdom.

Proposed EMCDDA standard to count acute drug-related deaths - the DRD standard, Version 1.0 (Box 2 OL)

Statistical tables
Number of acute drug-related deaths recorded in EU countries (national definitions used to report to the EMCDDA), 1985-99

Acute drug-related deaths according to the new European DRD-Standard for General Mortality Registers and for Special Registers


Law-enforcement indicators

'Arrests' for drug offences

Figures
Drug most frequently involved in the 'arrests' for drug offences in the EU (Figure 12, map)

'Arrests' for drug offences in EU countries 1991-99: three years' moving average indexed (1991 = 100) (Figure 13, line chart)

Statistical tables
Arrests for drug offences, 1991-99. Three year moving averages indexed (1991 = 100)

Number of 'arrests' for drug law offences in EU countries, 1985-99 (Table 3 OL)

Drug most frequently involved in the 'arrests' for drug offences

Offence type most frequently involved in the 'arrests' for drug offences

Drugs users in prison

Statistical tables
Proportion of drug users among prisoners in EU countries: Belgium and Denmark, France, Germany and Greece, Ireland, Italy and Luxemburg, Netherlands, Austria, Spain, Finland and Sweden, United Kingdom (Table 4 OL)


Drug-market indicators

Seizures

Figures
Number of cannabis, heroin, cocaine, amphetamines, ecstasy and LSD seizures in EU countries (1985-99) (Figure 15, map)

Quantities of cannabis, coaine, heroin and amphetamines seized in EU countries (1985-99) (Figure 16, map)

Statistical tables
Drug seizures in the EU countries, 1999 (Table 5 OL)

Cannabis

Figures
Number of cannabis seizures in 1999 (Figure 14 OL, map)

Statistical tables
Number of cannabis seizures, 1985-1999

Quantities of cannabis seized, 1985-1999 (kgs)

Heroin

Figures
Number of heroin seizures in 1999 (Figure 14, map)

Statistical tables
Number of heroin seizures, 1985-1999

Quantities of heroin seized, 1985-1999 (kgs)

Cocaine

Figures
Number of cocaine seizures in 1999 (Figure 12 OL, map)

Statistical tables
Number of cocaine seizures, 1985-1999

Quantities of cocaine seized, 1985-1999 (kgs)

Amphetamines

Figures
Number of amphetamines seizures in 1999 (Figure 13 OL, map)

Statistical tables
Number of Amphetamine seizures, 1985-1999

Quantities of Amphetamines seized, 1985-1999 (kgs)

Ecstasy

Figure
Number of ecstasy seizures in 1999 (Figure 32, map)

Statistical tables
Number of Ecstasy seizures, 1985-1999

Quantities of Ecstasy seized, 1985-1999 (tablets)

LSD

Statistical tables
Number of LSD seizures, 1985-1999

Quantities of LSD seized, 1985-1999 (doses)


Political and strategic responses - At national level


Figures

Development of a drugs strategy - a cyclical process (Figure 17, graphic)

Horizontal holistic coordination (Figure 19, graphic)

Specific domain coordination (Figure 20, graphic)

Demand reduction


Figures
Classification of concepts in demand reduction (Figure 21)

Statistical tables
Substitution treatment among problem drug users (Table 1)

Assistance to drug users in prison in the EU (Table 2)

Cocaine - selected issue

Figures
Lifetime prevalence of cocaine and cannabis among 15 to 16-year-old school students (Figure 22, bar chart)

Lifetime prevalence of cocaine in targeted users surveys compared with populations surveys (Table 3)

Cocaine: trends for new clients admitted to treatment (Figure 15 OL, line chart)

Example of localised increase in percentage of cocaine and crack users in Frankfurt (total addicts registerd by police 1995-99) (Figure 23, line chart)

Synthetic drugs - selected issue

Figure
Ecstasy and amphetamine clients in outpatient addiction care in the Netherlands (Figure 31)

Central and east European countries

Figure
Lifetime experience of any illegal drugs (all students - ESPAD) (Figure 33, bar chart)

Tables
Lifetime experience of ecstasy, amphetamines and LSD use among schoolchildren, ESPAD 1995-99 (Table 4)

Number of demands for treatment in the CEECs since 1993 (all demands) (Table 5)

 

EMCDDA 2001 | home | webmaster | disclaimer